Stanley H. Hsia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stanley H. Hsia has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Martin L. Lee
Division of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California
2 shared publicationsPetra Duran
Division of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California
2 shared publications- Alastair W. Knights
Eli Lilly and Company Indianapolis Indiana USA
1 shared publication - Candice Goldstein
Department of General Studies, College of Science and Health, Charles R. Drew University of Medicine and Science, 1731 East 120 Street, Los Angeles, CA 90059, USA
1 shared publication - Cyrus V. Desouza
Division of Diabetes, Endocrinology & Metabolism, University of Nebraska Medical Center, Omaha Veterans Affairs Medical Center, Omaha, NE
1 shared publication Elisa Gomez-Valderas
Eli Lilly and Company, Indianapolis, Indiana (R.J.H., E.G.-V., M.Z., E.R., J.K., P.S., A.K., V.T.T.)
1 shared publication
Latest Publications
- 26 May 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (7) , 917-928
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines and clinical practice. To assess the efficacy and safety of tirzepatide versus intensified conventional care (ICC) in participants with early T2D who have inadequate glycemic control with diet, exercise, and metformin. Randomized, open-label, parallel-group, phase 4 trial (SURPASS-EARLY). (ClinicalTrials.gov: NCT05433584). 78 sites in 10 countries. 794 adults with at most 4 years of T2D history treated with metformin. Tirzepatide (15 mg or maximum tolerated dose) or ICC (including GLP-1RAs but excluding tirzepatide) used in clinical practice and supported by local treatment guidelines. The primary objective was to show the noninferiority of tirzepatide to ICC for change in hemoglobin A1c (HbA1c) from baseline to 2 years. Secondary objectives were to show the superiority of tirzepatide for change in HbA1c, weight, and waist circumference. Tirzepatide was superior to ICC for mean changes from baseline to 2 years in HbA1c (-1.99 percentage points [95% CI, -2.12 to -1.87 percentage points] vs. -1.32 percentage points [CI, -1.44 to -1.19 percentage points]; estimated treatment difference [ETD], -0.68 percentage points [CI, -0.84 to -0.51 percentage points]; P < 0.001), weight (ETD, -8.0 kg [CI, -9.39 to -6.50 kg]; P < 0.001), and waist circumference (ETD, -6.2 cm [CI, -7.54 to -4.93 cm]; P < 0.001) (treatment regimen estimand). More participants achieved normoglycemia (HbA1c 1c, weight, and waist circumference, and more participants achieved normoglycemia (HbA1c <5.7%) with tirzepatide than ICC after 2 years. Eli Lilly and Company.
- 26 May 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (7) , 917-928
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines and clinical practice. To assess the efficacy and safety of tirzepatide versus intensified conventional care (ICC) in participants with early T2D who have inadequate glycemic control with diet, exercise, and metformin. Randomized, open-label, parallel-group, phase 4 trial (SURPASS-EARLY). (ClinicalTrials.gov: NCT05433584). 78 sites in 10 countries. 794 adults with at most 4 years of T2D history treated with metformin. Tirzepatide (15 mg or maximum tolerated dose) or ICC (including GLP-1RAs but excluding tirzepatide) used in clinical practice and supported by local treatment guidelines. The primary objective was to show the noninferiority of tirzepatide to ICC for change in hemoglobin A1c (HbA1c) from baseline to 2 years. Secondary objectives were to show the superiority of tirzepatide for change in HbA1c, weight, and waist circumference. Tirzepatide was superior to ICC for mean changes from baseline to 2 years in HbA1c (-1.99 percentage points [95% CI, -2.12 to -1.87 percentage points] vs. -1.32 percentage points [CI, -1.44 to -1.19 percentage points]; estimated treatment difference [ETD], -0.68 percentage points [CI, -0.84 to -0.51 percentage points]; P < 0.001), weight (ETD, -8.0 kg [CI, -9.39 to -6.50 kg]; P < 0.001), and waist circumference (ETD, -6.2 cm [CI, -7.54 to -4.93 cm]; P < 0.001) (treatment regimen estimand). More participants achieved normoglycemia (HbA1c 1c, weight, and waist circumference, and more participants achieved normoglycemia (HbA1c <5.7%) with tirzepatide than ICC after 2 years. Eli Lilly and Company.
- Open Access
- 1 March 2021
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 23, 100249
Metabolic parameters in smokers undergoing smoking reduction
- 1 March 2021
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 23, 100249
Open AccessMetabolic parameters in smokers undergoing smoking reduction
- Open Access
- 25 October 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3) , 677-687
Results of a Study Comparing Glycated Albumin to Other Glycemic Indices
Context Intermediate-term glycemic control metrics fulfill a need for measures beyond hemoglobin A1C. Objective Compare glycated albumin (GA), a 14-day blood glucose measure, with other glycemic indices. Design 24-week prospective study of assay performance. Setting 8 US clinics. Participants Subjects with type 1 (n = 73) and type 2 diabetes (n = 77) undergoing changes to improve glycemic control (n = 98) or with stable diabetes therapy (n = 52). Interventions GA, fructosamine, and A1C measured at prespecified intervals. Mean blood glucose (MBG) calculated using weekly self-monitored blood glucose profiles. Main Outcome Measures Primary: Pearson correlation between GA and fructosamine. Secondary: magnitude (Spearman correlation) and direction (Kendall correlation) of change of glycemic indices in the first 3 months after a change in diabetes management. Results GA was more concordant (60.8%) with changes in MBG than fructosamine (55.5%) or A1C (45.5%). Across all subjects and visits, the GA Pearson correlation with fructosamine was 0.920. Pearson correlations with A1C were 0.655 for GA and 0.515 for fructosamine (P < .001) and with MBG were 0.590 and 0.454, respectively (P < .001). At the individual subject level, Pearson correlations with both A1C and MBG were higher for GA than for fructosamine in 56% of subjects; only 4% of subjects had higher fructosamine correlations with A1C and MBG. GA had a higher Pearson correlation with A1C and MBG in 82% and 70% of subjects, respectively. Conclusions Compared with fructosamine, GA correlates significantly better with both short-term MBG and long-term A1C and may be more useful than fructosamine in clinical situations requiring monitoring of intermediate-term glycemic control (NCT02489773).
- 25 October 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3) , 677-687
Open AccessResults of a Study Comparing Glycated Albumin to Other Glycemic Indices
Context Intermediate-term glycemic control metrics fulfill a need for measures beyond hemoglobin A1C. Objective Compare glycated albumin (GA), a 14-day blood glucose measure, with other glycemic indices. Design 24-week prospective study of assay performance. Setting 8 US clinics. Participants Subjects with type 1 (n = 73) and type 2 diabetes (n = 77) undergoing changes to improve glycemic control (n = 98) or with stable diabetes therapy (n = 52). Interventions GA, fructosamine, and A1C measured at prespecified intervals. Mean blood glucose (MBG) calculated using weekly self-monitored blood glucose profiles. Main Outcome Measures Primary: Pearson correlation between GA and fructosamine. Secondary: magnitude (Spearman correlation) and direction (Kendall correlation) of change of glycemic indices in the first 3 months after a change in diabetes management. Results GA was more concordant (60.8%) with changes in MBG than fructosamine (55.5%) or A1C (45.5%). Across all subjects and visits, the GA Pearson correlation with fructosamine was 0.920. Pearson correlations with A1C were 0.655 for GA and 0.515 for fructosamine (P < .001) and with MBG were 0.590 and 0.454, respectively (P < .001). At the individual subject level, Pearson correlations with both A1C and MBG were higher for GA than for fructosamine in 56% of subjects; only 4% of subjects had higher fructosamine correlations with A1C and MBG. GA had a higher Pearson correlation with A1C and MBG in 82% and 70% of subjects, respectively. Conclusions Compared with fructosamine, GA correlates significantly better with both short-term MBG and long-term A1C and may be more useful than fructosamine in clinical situations requiring monitoring of intermediate-term glycemic control (NCT02489773).
- 1 October 2019
- Published by Wiley in Journal of Diabetes
- Vol. 12 (1) , 91-94
Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third‐line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study
Highlights The anti‐inflammatory agent, hydroxychloroquine, improved glycemic control in type 2 diabetes patients when used as a third‐line agent added to metformin and a sulfonylurea. In comparison to pioglitazone, hydroxychloroquine lowered hemoglobin A1c levels less effectively and did not improve insulin sensitivity, but also did not cause any weight gain, hypoglycemia, or pedal edema. In this small, proof‐of‐concept study, hydroxychloroquine was well tolerated and may be an alternative treatment choice in combination with other agents.
- 1 October 2019
- Published by Wiley in Journal of Diabetes
- Vol. 12 (1) , 91-94
Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third‐line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study
Highlights The anti‐inflammatory agent, hydroxychloroquine, improved glycemic control in type 2 diabetes patients when used as a third‐line agent added to metformin and a sulfonylurea. In comparison to pioglitazone, hydroxychloroquine lowered hemoglobin A1c levels less effectively and did not improve insulin sensitivity, but also did not cause any weight gain, hypoglycemia, or pedal edema. In this small, proof‐of‐concept study, hydroxychloroquine was well tolerated and may be an alternative treatment choice in combination with other agents.
- Open Access
- 5 April 2013
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 7 (6) , 675-682
Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States
- 5 April 2013
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 7 (6) , 675-682
Open AccessDifferences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States
- 1 April 2013
- Published by Elsevier in Primary Care Diabetes
- Vol. 7 (1) , 51-55
Psychological insulin resistance among low-income, U.S. racial minority patients with type 2 diabetes
- 1 April 2013
- Published by Elsevier in Primary Care Diabetes
- Vol. 7 (1) , 51-55
Psychological insulin resistance among low-income, U.S. racial minority patients with type 2 diabetes
- 1 September 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17 (5) , 691-698
Sitagliptin Compared with Thiazolidinediones as a Third-Line Oral Antihyperglycemic Agent in Type 2 Diabetes Mellitus
- 1 September 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17 (5) , 691-698
Sitagliptin Compared with Thiazolidinediones as a Third-Line Oral Antihyperglycemic Agent in Type 2 Diabetes Mellitus
- 13 December 2010
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 91 (3) , 293-299
Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients
- 13 December 2010
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 91 (3) , 293-299
Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients